We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, lost 0.82%.
Shares of the drugmaker have depreciated by 0.05% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. On that day, Vertex Pharmaceuticals is projected to report earnings of $4.21 per share, which would represent year-over-year growth of 132.81%. At the same time, our most recent consensus estimate is projecting a revenue of $2.88 billion, reflecting a 8.87% rise from the equivalent quarter last year.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $17.82 per share and revenue of $11.91 billion. These results would represent year-over-year changes of +4142.86% and +8.04%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% lower. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Vertex Pharmaceuticals is at present trading with a Forward P/E ratio of 24.99. This represents a premium compared to its industry average Forward P/E of 18.72.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 85, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, lost 0.82%.
Shares of the drugmaker have depreciated by 0.05% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. On that day, Vertex Pharmaceuticals is projected to report earnings of $4.21 per share, which would represent year-over-year growth of 132.81%. At the same time, our most recent consensus estimate is projecting a revenue of $2.88 billion, reflecting a 8.87% rise from the equivalent quarter last year.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $17.82 per share and revenue of $11.91 billion. These results would represent year-over-year changes of +4142.86% and +8.04%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% lower. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Vertex Pharmaceuticals is at present trading with a Forward P/E ratio of 24.99. This represents a premium compared to its industry average Forward P/E of 18.72.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 85, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.